Apollomics Inc., a biopharmaceutical company, has received a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3. The SEC's correspondence, dated April 15, 2024, is a follow-up to Apollomics' response on April 12, 2024, and requests further amendments to the registration statement. The SEC has specifically asked Apollomics to reconcile conflicting information about the residency of its board members. The company had previously indicated that all board members reside outside of China, yet the filing suggests two directors are based in mainland China. The SEC has invited Apollomics to either amend the registration statement or explain why such an amendment is not necessary. The company is expected to respond to the SEC's request, and further comments from the SEC may follow upon review of the amendments and the company's response.

Apollomics Inc., a biopharmaceutical company, has received a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3. The SEC's correspondence, dated April 15, 2024, is a follow-up to Apollomics' response on April 12, 2024, and requests further amendments to the registration statement. The SEC has specifically asked Apollomics to reconcile conflicting information about the residency of its board members. The company had previously indicated that all board members reside outside of China, yet the filing suggests two directors are based in mainland China. The SEC has invited Apollomics to either amend the registration statement or explain why such an amendment is not necessary. The company is expected to respond to the SEC's request, and further comments from the SEC may follow upon review of the amendments and the company's response.